MultiCell Technologies Inc (MCET)

[TPX]

Granted Patent Drug names are called: CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!

Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA).
https://www.lens.org/lens/patent/167-627-709-236-287/fulltext

INTRODUCTION
Primary cultures of human hepatocytes are widely used to evaluate the cytochrome P450 (CYP) enzyme-inducing potential and/or toxicity of drug candidates. However, the availability of human hepatocytes for this purpose is limited and erratic, and there are large inter-individual differences in the magnitude of induction (due to differences in both
"control" and "induced" CYP activities). Immortalized human hepatocytes, Fa2N-4, developed by Multicell Technologies, (Warwick, RI) have the potential to overcome these limitations. The cells, immortalized through transformation of human hepatocytes with SV40 T antigen, display in vitro cell morphology that closely resembles primary human hepatocytes (Figure 1). The Fa2N-4 cells retain many of the characteristics of primary hepatocytes, including the inducibility of multiple CYP mRNAs and enzyme activities (Mills et al., 2002; Morris et al., 2003; Czerwinski et al., 2003). In this study, we further characterized the ability of these cells to respond to enzymeinducing xenobiotics. Additionally, we examined the toxicity profile of multiple enzyme inducers in primary hepatocytes and Fa2N-4 cells.

MATERIALS AND METHODS
The Fa2N-4 cells were propagated in MFE media (Multicell Technologies) on plasticware coated with Vitrogen (Cohesion Technologies, Palo Alto, CA) and maintained at 37°C, 5% CO2, 95% humidity. Immortalized hepatocytes were grown to confluency in 24 or 96-well plates and treated with enzyme inducers for up to 6 consecutive days with daily changes of medium. All enzyme inducers were dissolved in
DMSO (final concentration of solvent 0.1%, v/v). Primary human hepatocytes were isolated and cultured as described (LeCluyse et al., 2000, Madan et al., 2003). Enzymatic activities were determined by incubating the cells with CYPspecific substrates. Metabolite formation was measured by LC-MS as summarized in Table 1.

The Use of Immortalized Hepatocytes in Induction Studies https://www.xenotech.com/access-adme-research-resources/resources/the-use-of-immortalized-hepatocytes-in-induction-studies/

https://www.xenotech.com/wp-content/uploads/2004/08/The-Use-of-Immortalized-Hepatocytes-in-Induction-Studies.pdf

Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany!

Multicell Technologies Immortalized Hepatocytes

InventorJin LiuRonald A. FarisCurrent Assignee Multicell Technologies Inc

US 7566567 B2
Doc Type: Granted Patent
ID: lens.org/167-627-709-236-287
Jul 28, 2009

Application US10/574,163 events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2007-01-04
Publication of US20070004039A1
2009-07-28
Publication of US7566567B2
2009-07-28
Application granted
Status
Active
2025-01-13
Adjusted expiration
https://patents.google.com/patent/US7566567B2/un

EP 1704227 B1
Doc Type: Granted Patent
ID: lens.org/097-040-197-694-101
Jan 27, 2010

EP1704227B1 European Patent Office

Application EP04794437A events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2006-09-27
Publication of EP1704227A1
2007-01-17
Publication of EP1704227A4
2010-01-27
Application granted
2010-01-27
Publication of EP1704227B1
Status
Active
2024-10-07
Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en

DE 602004025380 D1
Doc Type: Granted Patent
ID: lens.org/082-791-344-403-259
Mar 18, 2010

Application DE602004025380T events
2003-10-10
Priority to US51050903P
2004-10-07
Application filed by Multicell Technologies Inc
2004-10-07
Priority to PCT/US2004/033091
2010-03-18
Publication of DE602004025380D1
Status
Active
2024-10-08
Anticipated expiration
https://patents.google.com/patent/DE602004025380/D1

Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family

Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-287